Cargando…

Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma

BACKGROUND: To evaluate the long‐term outcomes after surgical resection for stage I lung adenocarcinoma based on the percentage of lepidic component (LC) and invasive tumor size (IS). METHODS: The clinicopathological characteristics of 1049 patients with stage I lung adenocarcinoma who underwent sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chia, Wang, Lei‐Chi, Chen, Hui‐Shan, Yeh, Yi‐Chen, Hsu, Po‐Kuei, Huang, Chien‐Sheng, Hsieh, Chih‐Cheng, Hsu, Han‐Shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284188/
https://www.ncbi.nlm.nih.gov/pubmed/35680127
http://dx.doi.org/10.1111/1759-7714.14477
_version_ 1784747508952465408
author Liu, Chia
Wang, Lei‐Chi
Chen, Hui‐Shan
Yeh, Yi‐Chen
Hsu, Po‐Kuei
Huang, Chien‐Sheng
Hsieh, Chih‐Cheng
Hsu, Han‐Shui
author_facet Liu, Chia
Wang, Lei‐Chi
Chen, Hui‐Shan
Yeh, Yi‐Chen
Hsu, Po‐Kuei
Huang, Chien‐Sheng
Hsieh, Chih‐Cheng
Hsu, Han‐Shui
author_sort Liu, Chia
collection PubMed
description BACKGROUND: To evaluate the long‐term outcomes after surgical resection for stage I lung adenocarcinoma based on the percentage of lepidic component (LC) and invasive tumor size (IS). METHODS: The clinicopathological characteristics of 1049 patients with stage I lung adenocarcinoma who underwent surgery between 2006 and 2016 were retrospectively reviewed. Tumors were categorized into groups: A (LC ≥ 50%) and B (LC < 50%). Groups A0 and A1 consisted of minimally invasive adenocarcinomas (MIA) and other lepidic‐predominant invasive adenocarcinomas, respectively. Group B was categorized into B1 (IS ≤ 1 cm), B2 (1 < IS≤2 cm), and B3 (2 < IS≤3 cm) by invasive tumor size and divided into subgroups (B1[lep+]/[lep−], B2[lep+]/[lep−], and B3[lep+]/[lep−]) according to the presence[lep+] or absence[lep−] of LCs. Cumulative incidence of recurrence (CIR) and cancer‐specific survival (CSS) were examined. RESULTS: LC decreased with increasing IS. Only 24 (8.5%) tumors in group A had an IS >1 cm. 10‐year CIR and CSS were 15.2% and 86.0%. LC and IS were found to be independent predictors of CSS. Patients in group A had 1.4% 10‐year CIR and 100% 10‐year CSS. In group B, a significantly higher CIR and worse CSS were observed as IS increased (p < 0.001), but LC was not a predictor for CSS (p = 0.593). No significant differences in CIR or CSS were found in presence of LC or not when LC < 50% (B1[lep+]/[lep−], B2[lep+]/[lep−], and B3[lep+]/[lep−]: p = 0.36/0.48, p = 0.82/0.94, and p = 0.90/0.37, respectively). CONCLUSIONS: LC≥50% tumors demonstrated excellent prognosis regardless of IS. The outcomes of LC < 50% tumors were well predicted by IS, corresponding to the T‐staging system. The predictive value of LC for prognosis became insignificant.
format Online
Article
Text
id pubmed-9284188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-92841882022-07-15 Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma Liu, Chia Wang, Lei‐Chi Chen, Hui‐Shan Yeh, Yi‐Chen Hsu, Po‐Kuei Huang, Chien‐Sheng Hsieh, Chih‐Cheng Hsu, Han‐Shui Thorac Cancer Original Articles BACKGROUND: To evaluate the long‐term outcomes after surgical resection for stage I lung adenocarcinoma based on the percentage of lepidic component (LC) and invasive tumor size (IS). METHODS: The clinicopathological characteristics of 1049 patients with stage I lung adenocarcinoma who underwent surgery between 2006 and 2016 were retrospectively reviewed. Tumors were categorized into groups: A (LC ≥ 50%) and B (LC < 50%). Groups A0 and A1 consisted of minimally invasive adenocarcinomas (MIA) and other lepidic‐predominant invasive adenocarcinomas, respectively. Group B was categorized into B1 (IS ≤ 1 cm), B2 (1 < IS≤2 cm), and B3 (2 < IS≤3 cm) by invasive tumor size and divided into subgroups (B1[lep+]/[lep−], B2[lep+]/[lep−], and B3[lep+]/[lep−]) according to the presence[lep+] or absence[lep−] of LCs. Cumulative incidence of recurrence (CIR) and cancer‐specific survival (CSS) were examined. RESULTS: LC decreased with increasing IS. Only 24 (8.5%) tumors in group A had an IS >1 cm. 10‐year CIR and CSS were 15.2% and 86.0%. LC and IS were found to be independent predictors of CSS. Patients in group A had 1.4% 10‐year CIR and 100% 10‐year CSS. In group B, a significantly higher CIR and worse CSS were observed as IS increased (p < 0.001), but LC was not a predictor for CSS (p = 0.593). No significant differences in CIR or CSS were found in presence of LC or not when LC < 50% (B1[lep+]/[lep−], B2[lep+]/[lep−], and B3[lep+]/[lep−]: p = 0.36/0.48, p = 0.82/0.94, and p = 0.90/0.37, respectively). CONCLUSIONS: LC≥50% tumors demonstrated excellent prognosis regardless of IS. The outcomes of LC < 50% tumors were well predicted by IS, corresponding to the T‐staging system. The predictive value of LC for prognosis became insignificant. John Wiley & Sons Australia, Ltd 2022-06-09 2022-07 /pmc/articles/PMC9284188/ /pubmed/35680127 http://dx.doi.org/10.1111/1759-7714.14477 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Liu, Chia
Wang, Lei‐Chi
Chen, Hui‐Shan
Yeh, Yi‐Chen
Hsu, Po‐Kuei
Huang, Chien‐Sheng
Hsieh, Chih‐Cheng
Hsu, Han‐Shui
Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title_full Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title_fullStr Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title_full_unstemmed Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title_short Outcomes of patients with different lepidic percentage and tumor size of stage I lung adenocarcinoma
title_sort outcomes of patients with different lepidic percentage and tumor size of stage i lung adenocarcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9284188/
https://www.ncbi.nlm.nih.gov/pubmed/35680127
http://dx.doi.org/10.1111/1759-7714.14477
work_keys_str_mv AT liuchia outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT wangleichi outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT chenhuishan outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT yehyichen outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT hsupokuei outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT huangchiensheng outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT hsiehchihcheng outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma
AT hsuhanshui outcomesofpatientswithdifferentlepidicpercentageandtumorsizeofstageilungadenocarcinoma